- Home
- PD vs RIGL Comparison
PD vs RIGL Comparison
Compare PD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | RIGL |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.9M | 628.4M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PD | RIGL |
|---|---|---|
| Price | $6.24 | $29.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $12.63 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 2.8M | 259.8K |
| Earning Date | 03-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 416.95 | ★ 1867.68 |
| EPS | 1.87 | ★ 19.48 |
| Revenue | ★ $492,546,000.00 | $294,282,000.00 |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $2.88 | $12.75 |
| P/E Ratio | $3.44 | ★ $1.47 |
| Revenue Growth | 5.36 | ★ 64.15 |
| 52 Week Low | $5.92 | $15.70 |
| 52 Week High | $17.45 | $52.24 |
Technical Indicators
Market Signals| Indicator | PD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 57.19 |
| Support Level | $6.08 | $28.08 |
| Resistance Level | $16.47 | $30.59 |
| Average True Range (ATR) | 0.35 | 1.03 |
| MACD | 0.05 | 0.69 |
| Stochastic Oscillator | 24.31 | 95.66 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.